Market Cap 5.26B
Revenue (ttm) 383.48M
Net Income (ttm) -146.37M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -38.17%
Debt to Equity Ratio 0.00
Volume 790,500
Avg Vol 1,221,414
Day's Range N/A - N/A
Shares Out 57.44M
Stochastic %K 92%
Beta 0.81
Analysts Strong Sell
Price Target $120.50

Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patient...

Industry: Medical Devices
Sector: Healthcare
Phone: 949 367 9600
Fax: 949 367 9984
Address:
One Glaukos Way, Aliso Viejo, United States
PrivateProfiteering
PrivateProfiteering Nov. 21 at 3:53 AM
$GKOS is currently trading at $95.2, above its 30-day moving average (MA30) of $84.84 and 50-day moving average (MA50) of $84.38, indicating a bullish trend. The RSI of 61.62 suggests that the stock is not overbought, providing room for further upward movement. The recent price is also closer to the 60-day high of $102.8, suggesting potential resistance at that level. Directional bias is bullish due to the price being above key moving averages and a healthy RSI. Suggested entry point is at $95.5, slightly above the last close to confirm upward momentum. Set a stop loss at $91.88, just below the recent support level indicated by the 60-day low of $73.16. Target 1 is set at $100, approaching the recent high, while Target 2 is at $102.8, aligning with the 60-day high. This plan capitalizes on the current bullish sentiment while managing risk effectively. https://privateprofiteers.com
0 · Reply
Iightning
Iightning Nov. 21 at 1:40 AM
1ightning® Options Trade Alert (Actionable) | Buy $GKOS Dec 19 $95 Call | Enter: $5.78 Exit: $11.32 | Profit: 96.07% ROI | https://1ightning.com
0 · Reply
PrivateProfiteering
PrivateProfiteering Nov. 20 at 9:10 AM
$GKOS: The current market context shows a last close at $90.03, with an RSI of 71.44, indicating overbought conditions. The price is above both the 30-day moving average (MA30) of $83.96 and the 50-day moving average (MA50) of $84.1, suggesting a bullish trend, but the high RSI signals potential for a pullback. The 60-day high is $102.8, while the low is $73.16, indicating a significant range. Directional bias leans bearish in the short term due to the overbought RSI, despite the bullish trend indicated by the moving averages. Suggested entry point: $88.50 (below current close to capture a potential pullback). Stop loss: $85.00 (to limit downside risk). Targets: $95.00 (first target) and $100.00 (second target) to capitalize on potential upward movement if momentum resumes. For further insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Iightning
Iightning Nov. 19 at 11:04 PM
1ightning® Options Trade Alert (Actionable) | Buy $GKOS Dec 19 $95 Call | Enter: $5.78 Exit: $11.32 | Profit: 96.07% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 7:22 AM
1ightning® Options Trade Alert (Actionable) | Buy $GKOS Dec 19 $95 Call | Enter: $5.78 Exit: $11.32 | Profit: 96.07% ROI | https://1ightning.com
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 9 at 9:44 PM
0 · Reply
QuantitativeTrading_
QuantitativeTrading_ Nov. 7 at 10:21 PM
$GKOS $CYBR $CAMT $VEEV Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off Brown Capital Management sold 376,359 shares of Glaukos for $34.6M in Q3. The sale represented about 1.4% of the fund's 13F assets. It retains 762,760 shares valued at $62.2M.
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 6 at 11:48 PM
$GKOS Share Price: $81.75 Contract Selected: Apr 17, 2026 $80 Calls Buy Zone: $10.71 – $13.23 Target Zone: $17.21 – $21.04 Potential Upside: 52% ROI Time to Expiration: 161 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 6 at 5:38 PM
$GKOS Brown Capital’s $34.6M sale didn’t shake confidence—Glaukos’ glaucoma implants, 22% revenue growth, and $475M sales forecast fuel optimism. https://biotechhealthx.com/biotech-news/why-glaukos-gkos-could-surge-30-in-2025/
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 4 at 9:48 PM
0 · Reply
Latest News on GKOS
Glaukos Corporation (GKOS) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 12:06 AM EDT - 22 days ago

Glaukos Corporation (GKOS) Q3 2025 Earnings Call Transcript


Glaukos Announces Third Quarter 2025 Financial Results

Oct 29, 2025, 4:05 PM EDT - 22 days ago

Glaukos Announces Third Quarter 2025 Financial Results


US FDA approves Glaukos' new eye therapy

Oct 20, 2025, 7:10 AM EDT - 4 weeks ago

US FDA approves Glaukos' new eye therapy


Glaukos Announces FDA Approval of Epioxa™

Oct 20, 2025, 7:00 AM EDT - 4 weeks ago

Glaukos Announces FDA Approval of Epioxa™


Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 5:15 AM EDT - 4 months ago

Glaukos Corporation (GKOS) Q2 2025 Earnings Call Transcript


Glaukos Announces Second Quarter 2025 Financial Results

Jul 30, 2025, 4:05 PM EDT - 4 months ago

Glaukos Announces Second Quarter 2025 Financial Results


Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript

Apr 30, 2025, 10:05 PM EDT - 7 months ago

Glaukos Corporation (GKOS) Q1 2025 Earnings Call Transcript


Glaukos Announces First Quarter 2025 Financial Results

Apr 30, 2025, 4:05 PM EDT - 7 months ago

Glaukos Announces First Quarter 2025 Financial Results


Glaukos Announces the Release of its 2024 Sustainability Report

Apr 16, 2025, 7:00 AM EDT - 7 months ago

Glaukos Announces the Release of its 2024 Sustainability Report


Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

Feb 24, 2025, 7:00 AM EST - 9 months ago

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™


Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript

Feb 21, 2025, 4:29 AM EST - 9 months ago

Glaukos Corporation (GKOS) Q4 2024 Earnings Call Transcript


Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Dec 23, 2024, 7:00 AM EST - 11 months ago

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™


Glaukos: Still Bullish, But Embedded Expectations Are Now High

Dec 21, 2024, 7:04 AM EST - 11 months ago

Glaukos: Still Bullish, But Embedded Expectations Are Now High


Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript

Nov 4, 2024, 11:03 PM EST - 1 year ago

Glaukos Corporation (GKOS) Q3 2024 Earnings Call Transcript


Glaukos Announces Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

Glaukos Announces Third Quarter 2024 Financial Results


Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript

Jul 31, 2024, 8:57 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q2 2024 Earnings Call Transcript


Glaukos Announces Second Quarter 2024 Financial Results

Jul 31, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces Second Quarter 2024 Financial Results


Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript

May 1, 2024, 8:42 PM EDT - 1 year ago

Glaukos Corporation (GKOS) Q1 2024 Earnings Call Transcript


Glaukos Announces First Quarter 2024 Financial Results

May 1, 2024, 4:05 PM EDT - 1 year ago

Glaukos Announces First Quarter 2024 Financial Results


PrivateProfiteering
PrivateProfiteering Nov. 21 at 3:53 AM
$GKOS is currently trading at $95.2, above its 30-day moving average (MA30) of $84.84 and 50-day moving average (MA50) of $84.38, indicating a bullish trend. The RSI of 61.62 suggests that the stock is not overbought, providing room for further upward movement. The recent price is also closer to the 60-day high of $102.8, suggesting potential resistance at that level. Directional bias is bullish due to the price being above key moving averages and a healthy RSI. Suggested entry point is at $95.5, slightly above the last close to confirm upward momentum. Set a stop loss at $91.88, just below the recent support level indicated by the 60-day low of $73.16. Target 1 is set at $100, approaching the recent high, while Target 2 is at $102.8, aligning with the 60-day high. This plan capitalizes on the current bullish sentiment while managing risk effectively. https://privateprofiteers.com
0 · Reply
Iightning
Iightning Nov. 21 at 1:40 AM
1ightning® Options Trade Alert (Actionable) | Buy $GKOS Dec 19 $95 Call | Enter: $5.78 Exit: $11.32 | Profit: 96.07% ROI | https://1ightning.com
0 · Reply
PrivateProfiteering
PrivateProfiteering Nov. 20 at 9:10 AM
$GKOS: The current market context shows a last close at $90.03, with an RSI of 71.44, indicating overbought conditions. The price is above both the 30-day moving average (MA30) of $83.96 and the 50-day moving average (MA50) of $84.1, suggesting a bullish trend, but the high RSI signals potential for a pullback. The 60-day high is $102.8, while the low is $73.16, indicating a significant range. Directional bias leans bearish in the short term due to the overbought RSI, despite the bullish trend indicated by the moving averages. Suggested entry point: $88.50 (below current close to capture a potential pullback). Stop loss: $85.00 (to limit downside risk). Targets: $95.00 (first target) and $100.00 (second target) to capitalize on potential upward movement if momentum resumes. For further insights, visit https://privateprofiteers.com. https://privateprofiteers.com
0 · Reply
Iightning
Iightning Nov. 19 at 11:04 PM
1ightning® Options Trade Alert (Actionable) | Buy $GKOS Dec 19 $95 Call | Enter: $5.78 Exit: $11.32 | Profit: 96.07% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 7:22 AM
1ightning® Options Trade Alert (Actionable) | Buy $GKOS Dec 19 $95 Call | Enter: $5.78 Exit: $11.32 | Profit: 96.07% ROI | https://1ightning.com
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 9 at 9:44 PM
0 · Reply
QuantitativeTrading_
QuantitativeTrading_ Nov. 7 at 10:21 PM
$GKOS $CYBR $CAMT $VEEV Brown Capital Sells $35 Million in Glaukos Stock After Sharp Sell-Off Brown Capital Management sold 376,359 shares of Glaukos for $34.6M in Q3. The sale represented about 1.4% of the fund's 13F assets. It retains 762,760 shares valued at $62.2M.
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 6 at 11:48 PM
$GKOS Share Price: $81.75 Contract Selected: Apr 17, 2026 $80 Calls Buy Zone: $10.71 – $13.23 Target Zone: $17.21 – $21.04 Potential Upside: 52% ROI Time to Expiration: 161 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
BioTechHealthX
BioTechHealthX Nov. 6 at 5:38 PM
$GKOS Brown Capital’s $34.6M sale didn’t shake confidence—Glaukos’ glaucoma implants, 22% revenue growth, and $475M sales forecast fuel optimism. https://biotechhealthx.com/biotech-news/why-glaukos-gkos-could-surge-30-in-2025/
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 4 at 9:48 PM
0 · Reply
TipRanks
TipRanks Nov. 4 at 11:11 AM
Beaten Down by 35%-Plus: Analysts Say These 2 Oversold Stocks Are Poised to Turn the Corner https://www.tipranks.com/news/article/beaten-down-by-35-plus-analysts-say-these-2-oversold-stocks-are-poised-to-turn-the-corner $XNCR $GKOS
0 · Reply
ninergizer
ninergizer Oct. 30 at 9:19 PM
$INVA This is next, we hit $CRNX and $GKOS 25 % plus. Do your DD. PDUFA Date: Dec 15, 2025 Zoliflodacin — Oral antibiotic for gonorrhea FDA Likelihood: Very high (Priority Review, strong Phase 3, urgent CDC priority). Market Impact: Medium–large public health value, smaller direct commercial revenue. U.S. gonorrhea cases ~700k/year (CDC). New oral option = government/NGO contracts, global demand, less private pricing power. Potential: Blockbuster public health win, but sales may be constrained by stewardship and generic pricing.
0 · Reply
PrinceRobert
PrinceRobert Oct. 30 at 7:56 PM
$GKOS close my eyes! 👀
0 · Reply
PrinceRobert
PrinceRobert Oct. 30 at 6:14 PM
$GKOS Is time to pull back yet?
0 · Reply
Toptradersam
Toptradersam Oct. 30 at 6:00 PM
$CMBM $MTSR $GKOS $QCLS LFG!!! https://www.youtube.com/watch?v=Fy13hc2ICuo
0 · Reply
ZacksResearch
ZacksResearch Oct. 30 at 4:27 PM
$GKOS narrowed its Q3 loss — but why is it still a sell? 🤔 📈 Revenue up 38% YoY on a reported basis, beating estimates by 9.5% 🔍 Strong adoption of iDose TR supports innovation, and FDA approval of Epioxa marks a milestone 🔻 Yet, it's a Zacks Rank #4 (Sell) stock Understand the risks before investing in GKOS 👉 https://www.zacks.com/stock/news/2781810/gkos-stock-surges-following-q3-earnings-revenue-beat-guidance-raised?cid=sm-stocktwits-2-2781810-body-18509&ADID=SYND_STOCKTWITS_TWEET_2_2781810_BODY_18509
0 · Reply
ZacksResearch
ZacksResearch Oct. 30 at 3:27 PM
$GKOS just crushed Q3 — and the stock’s flying 🚀 Narrower loss, 38% revenue growth, and a raised 2025 outlook show iDose TR and Epioxa are driving serious momentum across Glaukos’ core franchises. Full earnings breakdown here 👉 https://www.zacks.com/stock/news/2781810/gkos-stock-surges-following-q3-earnings-revenue-beat-guidance-raised?cid=sm-stocktwits-2-2781810-teaser-18508&ADID=SYND_STOCKTWITS_TWEET_2_2781810_TEASER_18508
0 · Reply
topstockalerts
topstockalerts Oct. 30 at 2:35 PM
$GKOS strong watch for today..
0 · Reply
TaoistTrader
TaoistTrader Oct. 30 at 1:35 PM
$GKOS rang the bell up 25% on some of my shares. 🍀
0 · Reply
topstockalerts
topstockalerts Oct. 30 at 11:48 AM
Pre Market Top Gainers PT2 $VIVS $GH $ARBB $PFSA $GKOS
0 · Reply
healthcareguru
healthcareguru Oct. 30 at 11:16 AM
$GKOS short it here, fade all day…next catalyst is November 12th Medicare CAC meeting where iDose could get its TAM crushed. 👎
0 · Reply
erevnon
erevnon Oct. 30 at 11:11 AM
BTIG maintains Glaukos $GKOS at Buy and raises the price target from $104 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply